Cargando…
IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824283/ https://www.ncbi.nlm.nih.gov/pubmed/35186402 http://dx.doi.org/10.6004/jadpro.2022.13.1.11 |
| _version_ | 1784646981267750912 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8824283 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Harborside Press LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88242832022-02-18 IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 J Adv Pract Oncol Meeting Reports Harborside Press LLC 2022-01 2022-02-02 /pmc/articles/PMC8824283/ /pubmed/35186402 http://dx.doi.org/10.6004/jadpro.2022.13.1.11 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Meeting Reports IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 |
| title | IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 |
| title_full | IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 |
| title_fullStr | IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 |
| title_full_unstemmed | IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 |
| title_short | IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021 |
| title_sort | idh-mutated aml: beyond enasidenib and ivosidenib monotherapy: highlights from soho 2021 |
| topic | Meeting Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824283/ https://www.ncbi.nlm.nih.gov/pubmed/35186402 http://dx.doi.org/10.6004/jadpro.2022.13.1.11 |